Page 115 - Read Online

Page 18 of 19 Davidson et al. J Cancer Metastasis Treat 2021;7:45 https://dx.doi.org/10.20517/2394-4722.2021.77

107. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 2013;13:572-83. DOI PubMed
PMC
108. Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer 2016;16:650-62. DOI PubMed
109. Maddocks OD, Labuschagne CF, Adams PD, Vousden KH. Serine metabolism supports the methionine cycle and DNA/RNA
methylation through de novo ATP synthesis in cancer cells. Mol Cell 2016;61:210-21. DOI PubMed PMC
110. Newman AC, Maddocks ODK. Serine and functional metabolites in cancer. Trends Cell Biol 2017;27:645-57. DOI PubMed
111. Shuvalov O, Petukhov A, Daks A, Fedorova O, Vasileva E, Barlev NA. One-carbon metabolism and nucleotide biosynthesis as
attractive targets for anticancer therapy. Oncotarget 2017;8:23955-77. DOI PubMed PMC
112. Wang H, Wang X, Xu L, Zhang J, Cao H. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse
prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets.
Purinergic Signal 2020;16:347-66. DOI PubMed PMC
113. He Q, Liu W, Sha S, et al. Adenosine 5'-monophosphate-activated protein kinase-dependent mTOR pathway is involved in
flavokawain B-induced autophagy in thyroid cancer cells. Cancer Sci 2018;109:2576-89. DOI PubMed PMC
114. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Potential activity of paclitaxel, vinorelbine and gemcitabine in
anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005;131:585-90. DOI PubMed
115. Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med
Oncol 2012;29:1421-8. DOI PubMed
116. Celano M, Calvagno MG, Bulotta S, et al. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma
cells. BMC Cancer 2004;4:63. DOI PubMed PMC
117. Shelton J, Lu X, Hollenbaugh JA, Cho JH, Amblard F, Schinazi RF. Metabolism, biochemical actions, and chemical synthesis of
anticancer nucleosides, nucleotides, and base analogs. Chem Rev 2016;116:14379-455. DOI PubMed PMC
118. Amini SK. Relative populations of some tautomeric forms of 2'-deoxyguanosine-5-fluorouridine mismatch. J Phys Chem B
2018;122:4433-44. DOI PubMed
119. Hu CM, Yeh MT, Tsao N, et al. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer
Cell 2012;22:36-50. DOI PubMed
120. Hossain MA, Asa TA, Rahman MM, et al. Network-based genetic profiling reveals cellular pathway differences between follicular
thyroid carcinoma and follicular thyroid adenoma. Int J Environ Res Public Health 2020;17:1373. DOI PubMed PMC
121. Gangjee A, Jain HD. Antifolates -- past, present and future. Curr Med Chem Anticancer Agents 2004;4:405-10. DOI PubMed
122. Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in
combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;20:1565-75. DOI PubMed
123. Pate JD, Gilbert CM, Bonucchi JT. Eradication of papillary thyroid carcinoma in a patient receiving pemetrexed and bevacizumAB.
AACE Clin Case Rep 2020;6:e247-51. DOI PubMed PMC
124. Sun WY, Kim HM, Jung WH, Koo JS. Expression of serine/glycine metabolism-related proteins is different according to the thyroid
cancer subtype. J Transl Med 2016;14:168. DOI PubMed PMC
125. Jeon MJ, You MH, Han JM, et al. High phosphoglycerate dehydrogenase expression induces stemness and aggressiveness in thyroid
cancer. Thyroid 2020;30:1625-38. DOI PubMed PMC
126. Liao L, Ge M, Zhan Q, et al. PSPH mediates the metastasis and proliferation of non-small cell lung cancer through MAPK signaling
pathways. Int J Biol Sci 2019;15:183-94. DOI PubMed PMC
127. Gao S, Ge A, Xu S, et al. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling
pathway in ER-negative breast cancer. J Exp Clin Cancer Res 2017;36:179. DOI PubMed PMC
128. Dekhne AS, Hou Z, Gangjee A, Matherly LH. Therapeutic targeting of mitochondrial one-carbon metabolism in Cancer. Mol Cancer
Ther ;2020:molcanther. DOI PubMed PMC
129. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010;35:427-33. DOI
PubMed PMC
130. Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: New views in health and disease. Trends
Biochem Sci 2018;43:752-89. DOI PubMed
131. Kim HM, Lee YK, Koo JS. Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget 2016;7:53628-41.
DOI PubMed PMC
132. Chen L, Cui H. Targeting glutamine induces apoptosis: a cancer therapy approach. Int J Mol Sci 2015;16:22830-55. DOI PubMed
PMC
133. Chiu M, Sabino C, Taurino G, et al. GPNA inhibits the sodium-independent transport system L for neutral amino acids. Amino Acids
2017;49:1365-72. DOI PubMed
134. Schulte ML, Fu A, Zhao P, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in
preclinical models. Nat Med 2018;24:194-202. DOI PubMed PMC
135. Jin H, Wang S, Zaal EA, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver
cancer. Elife 2020;9:e56749. DOI PubMed PMC
136. Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH. Phenylacetate inhibits growth and vascular endothelial growth factor
secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 1999;84:2840-7.
DOI PubMed
137. Häfliger P, Graff J, Rubin M, et al. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent
mouse model. J Exp Clin Cancer Res 2018;37:234. DOI PubMed PMC